(Q35570952)

8 August 2017

1 reference

title

Dopamine agonists in Parkinson's disease (English)

1 reference

8 August 2017

Dopamine agonists in Parkinson’s disease (English)

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

26 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

26 March 2024

2

Joseph Jankovic

1 reference

8 August 2017

Ron Tintner

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/13543784.12.11.1803

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Expert Opinion on Investigational Drugs

26 March 2024

published in

1 reference

8 August 2017

volume

12

1 reference

8 August 2017

issue

11

1 reference

8 August 2017

page(s)

1803-1820

1 reference

Evolution of the response to levodopa during the first 4 years of therapy.

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

A review of pramipexole and its clinical utility in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Excitation by dopamine of rat subthalamic nucleus neurones in vitro-a direct action with unconventional pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Distinct functions of the two isoforms of dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Phenotypic resolution of spontaneous and D1-like agonist-induced orofacial movement topographies in congenic dopamine D1A receptor 'knockout' mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

New insights into dopaminergic receptor function using antisense and genetically altered animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

The dopamine D(4) receptor: one decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Fibrotic valvular heart disease subsequent to bromocriptine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pergolide in the treatment of patients with early and advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Valvular heart disease in patients taking pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Clinical pharmacokinetics of cabergoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Ropinirole: a review of its use in the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Clinical pharmacokinetics of ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Warfarin and ropinirole interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dosing with ropinirole in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Apomorphine: an underutilized therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Ropinirole for the treatment of tremor in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dystonia and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Initial agonist treatment of Parkinson disease: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dopamine agonist monotherapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

The use of dopamine agonists in very elderly patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Neuroprotection and dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Switching from pergolide to pramipexole in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pergolide mesilate may improve fatigue in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Quick titration of pergolide in cotreatment with domperidone is safe and effective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Erythromelalgia: new theories and new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pergolide-induced pleuropulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Cabergoline in Parkinson's disease complicated by motor fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Parkinson's disease and sleepiness: an integral part of PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Daytime sleepiness and other sleep disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dopamine agonists induce episodes of irresistible daytime sleepiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Dual dopamine agonist treatment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Cost effectiveness of pramipexole in Parkinson's disease in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Clinical Characteristics of Pramipexole-Induced Peripheral Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1803

Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder.

21 January 2018

7

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Direct and indirect actions of dopamine on the membrane potential in medium spiny neurons of the mouse neostriatum

26 March 2024

8

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions

26 March 2024

10

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Effect of D1 receptor stimulation in normal and MPTP monkeys

26 March 2024

13

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Selective D-1 dopamine receptor agonist treatment of Parkinson's disease

26 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.

26 March 2024

20

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Double dissociation of serotonergic and dopaminergic mechanisms on attentional performance using a rodent five-choice reaction time task

26 March 2024

25

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions

26 March 2024

29

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Suggestive evidence for bromocriptine-induced pleurisy

26 March 2024

32

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy

26 March 2024

34

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine

26 March 2024

35

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

26 March 2024

Q64765326

39

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Double-blind assessment of potential pergolide-induced cardiotoxicity

26 March 2024

41

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease

26 March 2024

42

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

26 March 2024

51

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.

26 March 2024

63

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

26 March 2024

64

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Pleuropulmonary disease associated with dopamine agonist therapy

26 March 2024

70

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset

26 March 2024

73

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Do dopamine agonists provide neuroprotection?

26 March 2024

90

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach

26 March 2024

107

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema

26 March 2024

108

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Pleural fibrosis associated with dihydroergocryptine treatment

26 March 2024

113

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Pleuropulmonary disease associated with dopamine agonist therapy

26 March 2024

116

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

26 March 2024

Q64863169

118

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Pleural fibrosis associated with dihydroergocryptine treatment

26 March 2024

120

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Sleep attacks and Parkinson's disease treatment

26 March 2024

124

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication

26 March 2024

129

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?

26 March 2024

130

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results

26 March 2024

133

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1803

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference